Which of the following criteria is MOST appropriate to define the animal species needed for the pre-clinical toxicity testing of a biotechnology product?

• A.Biological activity with species and/or tissue specificity
• B.Immunochemical and functional tests
• C.Proposed product route and frequency of administration
• D.Proposed dose and volume of administration

Comment: *

Name: *

Email: *

Verification: *

A company is developing a new line of products in an area that is new to the company.
What is the BEST approach?

• A.Ask the trade association representative to provide an overview of the new product area to the marketing team.
• B.Summarize regulatory documents and history and provide the information to the management team.
• C.Obtain competitor research and provide the information to the management team.
• D.Obtain regulatory documents and history and provide the information to R&D.

Comment: *

Name: *

Email: *

Verification: *

A company is currently marketing an implantable orthopedic medical device. The R&D department is planning to change the material used for the implant. The R&D department states that the change does not impact the safety and effectiveness of the product.
What action should the regulatory affairs professional take FIRST?

• A.No action is needed in this situation.
• B.Write a memo to file since the change does not impact product safety and effectiveness.
• C.Prepare regulatory submissions that detail the medical device's change in materials.
• D.Review the content of change and supporting data for the equivalency with the current material.

Comment: *

Name: *

Email: *

Verification: *

Which of the following double-blind clinical trial designs would be MOST appropriate for a
Phase III study with a new product intended to treat an acute life-threatening disease with less than optimal available therapy?

• A.Active-controlled
• B.Placebo-controlled
• C.Dose-ranging
• D.Cross-over

Comment: *

Name: *

Email: *

Verification: *

When applying for marketing approval of a drug for a rare disease, which requirement can be waived?

• A.Pre-clinical studies
• B.Phase III clinical trials
• C.Phase I and II clinical trials
• D.Phase I clinical trials

Comment: *

Name: *

Email: *

Verification: *